User login
S3-01. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
Tutt A et al.
S3-08. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor–positive (HR+) early breast cancer (BC): Analysis of the SOFT trial
Francis PA et al.
S3-09. Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor–positive (HR+) breast cancer (BC)
Ribi K et al.
S6-01. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Hurvitz SA et al.
S1-09. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
Nanda R et al.
Dr. Hope S. Rugo is professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.
S3-01. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
Tutt A et al.
S3-08. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor–positive (HR+) early breast cancer (BC): Analysis of the SOFT trial
Francis PA et al.
S3-09. Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor–positive (HR+) breast cancer (BC)
Ribi K et al.
S6-01. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Hurvitz SA et al.
S1-09. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
Nanda R et al.
Dr. Hope S. Rugo is professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.
S3-01. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
Tutt A et al.
S3-08. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor–positive (HR+) early breast cancer (BC): Analysis of the SOFT trial
Francis PA et al.
S3-09. Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor–positive (HR+) breast cancer (BC)
Ribi K et al.
S6-01. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Hurvitz SA et al.
S1-09. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
Nanda R et al.
Dr. Hope S. Rugo is professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.
FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM
